Test of an Inhibitory Learning Model of Extinction in Treatment of Anxious Youth
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03372915 |
|
Recruitment Status :
Completed
First Posted : December 14, 2017
Last Update Posted : December 17, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Anxiety Disorders | Behavioral: Standard Exposure Behavioral: Exposure + Inhibitory Learning | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 28 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Treatment |
| Official Title: | Testing an Inhibitory Learning Model of Extinction in Exposure-Based Anxiety Treatment for Youth: Feasibility, Acceptability, and Efficacy |
| Actual Study Start Date : | January 31, 2018 |
| Actual Primary Completion Date : | December 1, 2020 |
| Actual Study Completion Date : | December 1, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Standard Exposure
This arm will receive exposure therapy conducted according to standard care practices.
|
Behavioral: Standard Exposure
Exposure therapy conducted according to standard clinical care practices |
|
Experimental: Exposure + Inhibitory Learning
This arm will receive exposure therapy conducted according to principles of inhibitory learning.
|
Behavioral: Exposure + Inhibitory Learning
Exposure therapy conducted according to practice recommendations based derived from research on inhibitory learning theories of fear extinction |
- Change in Percentage of Exposure Refusals (Feasibility Measure) [ Time Frame: Treatment weeks 5, 6, 7, and 8 ]Therapists will record the percentage of exposures the patient refused to complete during the session.
- Change in Latency to Initiating Exposure (Feasibility Measure) [ Time Frame: Treatment weeks 5, 6, 7, 8 ]Therapist will record the average amount of time the patient delayed before initiating each exposure in session
- Early Treatment Termination (Feasibility Measure) [ Time Frame: Measure will be collected following the patient's termination from treatment ]Information will be collected regarding whether the patient terminated treatment early (before session 9)
- Change in Homework Completion (Feasibility Measure) [ Time Frame: Treatment weeks 6, 7, 8, and 9 ]Therapist will record the number of exposure sessions for which the patient completed homework
- Client Satisfaction Questionnaire-8 (CSQ-8) [ Time Frame: Week 9 (End of Treatment) ]8-item measure of patient satisfaction with treatment. The measure is rated on a four-point scale, with possible scores ranging from 8-32.
- Change in Distress Tolerance Scale--Child (DTS-C) [ Time Frame: Treatment Week 1, Week 5, and Week 9 (End of Treatment) ]A 15-item self-report measure of difficulties managing distress and related emotions. The measure is rated on a 5-point scale, with possible scores ranging from 15 to 65. Higher scores indicate greater ability to tolerate distress.
- Change in Child Avoidance Measure, Self and Parent Report (CAMS/P) [ Time Frame: Treatment Week 1, Week 5, and Week 9 (End of Treatment) ]The CAMS/P are 8-item child- and parent-report (respectively) measures of behavioral avoidance. The measure is rated on a 4-point scale, with possible scores ranging from 0 to 24. Higher scores indicate greater behavioral avoidance.
- Change in Avoidance and Fusion Questionnaire--Youth (AFQ-Y) [ Time Frame: Treatment Week 1, Week 5, and Week 9 (End of Treatment) ]A 17-item self-report measure of experiential avoidance and cognitive fusion. The measure is rated on a 4-point scale, with possible scores ranging from 0 to 68. Higher scores indicate greater cognitive fusion and experiential avoidance.
- Change in Parent Acceptance and Action Questionnaire (PAAQ) [ Time Frame: Treatment Week 1, Week 5, and Week 9 (End of Treatment) ]A 15-item measure of parent experiential avoidance, or parental actions intended to control the form and frequency of their child's emotional experiences. Items are rated on a 7-point scale, with possible scores ranging from 17 to 105. Higher scores indicate less parental experiential avoidance and less effort to control child emotional experiences.
- Change in Screen for Child Anxiety Related Disorders (SCARED), Self and Parent Report [ Time Frame: Treatment Week 1, Week 5, Week 6, Week 7, Week 8, and Week 9 (End of Treatment) ]A 41-item child- and parent-report measure assessing symptoms of anxiety in youth ages 7 to 19. Items are rated on a 3-point scale, with scores ranging from 0 to 82. Higher scores indicate greater anxiety symptoms.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 7 Years to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Primary or secondary diagnosis of an anxiety disorder
- Ability of both child and caregiver to read and understand English
- Ability of child and at least one caregiver to attend weekly sessions
Exclusion Criteria:
- Diagnosis of autism spectrum disorder, intellectual development disorder, or limited cognitive functioning (i.e., documented Intelligence Quotient [IQ]<80).
- Diagnosis of a psychotic disorder or bipolar disorder
- Severe and current suicidal ideation, history of suicide attempt in past six months, or frequent and persistent self-injurious behavior
- Diagnosis of a substance use disorder or significant, recent substance use
- Any youth receiving concurrent individual therapy will also be excluded from the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03372915
| United States, Colorado | |
| Children's Hospital Colorado | |
| Aurora, Colorado, United States, 80045 | |
| Principal Investigator: | Jessica Hawks, PhD | University of Colorado, Denver |
| Responsible Party: | University of Colorado, Denver |
| ClinicalTrials.gov Identifier: | NCT03372915 |
| Other Study ID Numbers: |
17-2040 |
| First Posted: | December 14, 2017 Key Record Dates |
| Last Update Posted: | December 17, 2020 |
| Last Verified: | December 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Anxiety Disorders Mental Disorders |

